Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report) today and set a price target of ...

Virtual Meeting to be held on April 28-30 hosted by B. Riley.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

Vgenomics a leading precision health company and Meril Genomics a trusted diagnostics and molecular biology provider have announced a groundbreaking partnership aimed at providing complementary ...

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary ...

NEW YORK, April 8, 2025 /PRNewswire/ -- VARON, a leading provider of respiratory solutions, is expanding access to high-quality home oxygen concentrators, helping individuals with respiratory ...

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary ...

Detailed price information for Trevi Therapeutics Inc (TRVI-Q) from The Globe and Mail including charting and trades.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in ...